Valuation

URGNUroGen Pharma Ltd.

StockNasdaqIsraelHealth careEU retail: available

−0.5% today · +67.2% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 19% of the instruments we score

Trend: among the best of its peers; priced higher than most peers. No dividend.

UroGen Pharma Ltd. (URGN) valuation against sector peers: free-cash-flow yield −9.6%, P/S 8.7.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricURGNSector medianvs median
P/E—22.4 · n=28—
P/B—3.6 · n=45—
P/S8.74.5 · n=4096% above
EV/EBIT—20.8 · n=28—
Free-cash-flow yield−9.6%3.5% · n=41379% below
Dividend yield0.00%0.12% · n=100100% below
Return on equity—6.8% · n=56—
Return on invested capital—7.0% · n=47—
Gross margin90.8%70.2% · n=3929% above
Net debt / EBITDA—1.39 · n=26—

Value factor: 2 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG21.36.517.95.9%2.5%9/10
NOVNNovartis AG21.26.417.85.9%2.9%10/10
AZNAstraZeneca plc25.75.420.94.5%1.9%6/10
AZNAstraZeneca PLC25.75.420.94.5%1.3%6/10
NVONovo Nordisk A/S11.25.99.85.2%4.8%7/10
GSKGSK plc13.84.811.38.1%3.7%10/10
SNYSanofi11.81.316.37.8%5.0%7/10
SANSanofi SA11.81.316.27.8%5.5%8/10
TEVATeva Pharmaceutical Industries Limited66.06.037.22.9%0.0%6/10
ALCAlcon34.71.527.35.1%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 05 Aug 2026